Comparison of clinical features and drug therapies among European and Latin American patients with juvenile dermatomyositis

Clinical and Experimental Rheumatology

Volumn 29, Issue 1, 2011, Pages 117-124

  Guseinova, Dinara ^a   Consolaro, Alessandro ^a   Trail, Lucia ^a   Ferrari, Cristina ^a   Pistorio, Angela ^a   Ruperto, Nicolino ^a   Buoncompagni, Antonella ^a   Pilkington, Clarissa ^b   Maillard, Susan ^c   Oliveira, Sheila K ^d   Sztajnbok, Flavio ^e   Cuttica, Ruben ^f   Corona, Fabrizia ^g   Katsicas, Maria Martha ^h   Russo, Ricardo ^h   Ferriani, Virginia ⁱ   Burgos Vargas, Ruben ^j   Solis Vallejo, Eunice ^k   Bandeira, Marcia ^l   Baca, Vicente ^m   Saad Magalhaes, Claudia ⁿ   Silva, Clovis A ⁱ   Barcellona, Roberto ^o   Breda, Luciana ^p   Cimaz, Rolando ^q   Gallizzi, Romina ^r   Garozzo, Rosaria ^s   Martino, Silvana ^t   Meini, Antonella ^u   Stabile, Achille ^v   Martini, Alberto ^a,w   Ravelli, Angelo ^a,w   more..

^a G GASLINI INSTITUTE   (Italy)

^b GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^e STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^f HOSPITAL GENERAL DE NIÑOS PEDRO DE ELIZALDE   (Argentina)

^g FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^h HOSPITAL DE PEDIATRÍA PROF DR JUAN P GARRAHAN   (Argentina)

ⁱ UNIVERSITY OF SÃO PAULO   (Brazil)

^j HOSPITAL GENERAL DE MÉXICO   (Mexico)

^k Centro Medical National la Raza   (Mexico)

^l HOSPITAL PEQUENO PRÍNCIPE   (Brazil)

^m INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

ⁿ SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^o Presidio Ospedaliera Ospedali Civili Riuniti   (Italy)

^p UNIVERSITY OF CHIETI   (Italy)

^q UNIVERSITY OF FLORENCE   (Italy)

^r UNIVERSITY OF MESSINA   (Italy)

^s UNIVERSITY OF CATANIA   (Italy)

^t UNIVERSITY OF TURIN   (Italy)

^u SPEDALI CIVILI   (Italy)

^v CATHOLIC UNIVERSITY   (Italy)

^w UNIVERSITY OF GENOA   (Italy)

more..

Author keywords

Clinical features; Disease course; Drug therapy; Juvenile dermatomyositis; Onset manifestations

Indexed keywords

ANTIMALARIAL AGENT; AZATHIOPRINE; BISPHOSPHONIC ACID DERIVATIVE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; IMMUNOGLOBULIN; METHOTREXATE; METHYLPREDNISOLONE; DRUG;

ADOLESCENT; AGE DISTRIBUTION; ARTHRITIS; ARTICLE; CALCINOSIS; CHILD; CLINICAL FEATURE; CONTROLLED STUDY; DERMATOMYOSITIS; DISEASE COURSE; DISEASE DURATION; DRUG CHOICE; DRUG MEGADOSE; DRUG USE; DYSPHAGIA; DYSPHONIA; ELECTROMYOGRAPHY; ENTEROPATHY; EUROPE; FEMALE; FEVER; GEOGRAPHIC DISTRIBUTION; GOTTRON PAPULE; HELIOTROPE RASH; HUMAN; HUMAN TISSUE; INFANT; JUVENILE DERMATOMYOSITIS; MAJOR CLINICAL STUDY; MALAR RASH; MALE; MUSCLE BIOPSY; MUSCLE WEAKNESS; ONSET AGE; PAPULE; PRESCHOOL CHILD; PRIORITY JOURNAL; RASH; RAYNAUD PHENOMENON; SCHOOL CHILD; SKIN ULCER; SOUTH AND CENTRAL AMERICA; VASCULITIS; CLASSIFICATION; CLINICAL TRIAL; COMPARATIVE STUDY; DEMOGRAPHY; ETHNOLOGY; HEALTH STATUS; HOSPITALIZATION; INTERNATIONAL COOPERATION; MULTICENTER STUDY;

ADOLESCENT; AGE OF ONSET; CHILD; CHILD, PRESCHOOL; DEMOGRAPHY; DERMATOMYOSITIS; EUROPE; FEMALE; HEALTH STATUS; HUMANS; INFANT; INTERNATIONAL COOPERATION; LATIN AMERICA; MALE; PHARMACEUTICAL PREPARATIONS; SEVERITY OF ILLNESS INDEX;

EID: 79955682214     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. th ed. Philadelphia: Elsevier Saunders, 2005, p. 407-441.
2. FELDMAN BM, RIDER LG, REED AM, PACHMAN LM: Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood. Lancet 2008; 371: 2201-12.
3. WEDDERBURN LR, LI CKC: Paediatric idiopathic inflammatory muscle disease. Best Pract Res Clin Rheumatol 2004; 18:345-58.
4. HUBER A, FELDMAN BM: Long-term outcomes in juvenile dermatomyositis: how did we get here and where are we going? Curr Rheumatol Rep 2005; 7: 441-6
5. HUBER AM, LANG B, LEBLANC CM et al.: Medium- and long-term functional outcomes in a multicenter cohort of children with juvenile dermatomyositis. Arthritis Rheum 2000; 43: 541-9.
6. RIDER LG, LACHENBRUCH PA, MONROE JB et al.: Damage extent and predictors in adult and juvenile dermatomyositis and polymyositis as determined with the myositis damage index. Arthritis Rheum 2009; 60: 3425-35
7. RAVELLI A, TRAIL L, FERRARI C et al.: Longterm outcome and prognostic factors of juvenile dermatomyositis: A multinational, multicenter study of 490 patients. Arthritis Care Res 2010; 62: 63-72
8. RAMANAN AV, CAMPBELL-WEBSTER N, OTA S et al.: The effectiveness of treating juvenile dermatomyositis with methotrexate and aggressively tapered corticosteroids. Arthritis Rheum 2005; 52: 3570-78.
9. AL-MAYOUF SM, LAXER RM, SCHNEIDER R, SILVERMAN ED, FELDMAN BM: Intravenous immunoglobulin therapy for juvenile dermatomyositis: efficacy and safety. J Rheumatol 2000; 27: 2498-503
10. HECKMATT J, HASSON N, SAUNDERS C et al.: Cyclosporin in juvenile dermatomyositis. Lancet 1989; 1: 1063-6.
11. COMPEYROT-LACASSAGNE S, FELDMAN BM: Inflammatory myopathies in children. Pediatr Clin North Am 2005; 52:493-520.
12. RAMANAN AV, FELDMAN BM: Clinical features and outcomes of juvenile dermatomyositis and other childhood onset myositis syndromes. Rheum Dis Clin North Am 2002; 28: 833-57.
13. SATO JO, SALLUM AM, FERRIANI VP et al.: A Brazilian registry of juvenile dermatomyositis: onset features and classification of 189 cases. Clin Exp Rheumatol 2009; 27: 1031-8.
14. BOHAN A, PETER JB: Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975; 292: 344-7.
15. BOHAN A, PETER JB: Polymyositis and dermatomyositis (second of two parts). N Engl J Med 1975; 292: 403-7.
16. SPENCER CH, HANSON V, SINGSEN BH, BERNSTEIN BH, KORNREICH HK, KING KK: Course of treated juvenile dermatomyositis. J Pediatr 1984; 105: 399-408.
17. BOWYER SL, BLANE CE, SULLIVAN DB, CASSIDY JT: Childhood dermatomyositis: factors predicting functional outcome and development of dystrophic calcification. J Pediatr 1983; 103: 882-8.
18. STRINGER E, SINGH-GREWAL D, FELDMAN BM: Predicting the course of juvenile dermatomyositis: Significance of early clinical and laboratory features. Arthritis Rheum 2008; 58: 3585-92.
19. ISENBERG DA, ALLEN E, FAREWELL V et al.: International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease. Rheumatology 2004; 43: 49-54.
20. th Ed. Baltimore: Villiams and Wilkins; 1993.
21. LOVELL DJ, LINDSLEY CB, RENNEBOHM RM et al.: Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies. II. The Childhood Myositis Assessment Scale (CMAS): a quantitative tool for the evaluation of muscle function. Arthritis Rheum 1999; 42: 2213-9.
22. BODE RK, KLEIN-GITELMAN MS, MILLER ML, LECHMAN TS, PACHMAN LM: Disease activity score for children with juvenile dermatomyositis: reliability and validity evidence. Arthritis Rheum 2003; 49: 7-15.
23. SINGH G, ATHREYA BH, FRIES JF, GOLDSMITH DP: Measurement of health status in children with juvenile rheumatoid arthritis. Arthritis Rheum 1994; 37: 1761-9.
24. RUPERTO N, RAVELLI A, PISTORIO A et al.: Cross-cultural adaptation and psychometric evaluation of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ) in 32 countries. Review of the general methodology. Clin Exp Rheumatol 2001; 19 (Suppl. 23): S1-9.
25. LANDGRAF JM, ABETZ L, WARE JE: The CHQ User's Manual.1st Ed. Boston, MA, USA: The Health Institute, New England Medical Center; 1996.
26. MEDSGER TA JR, DAWSON WN JR, MASI AT: The epidemiology of polymyositis. Am J Med 1970; 48: 715-23.
27. PACHMAN LM, LIPTON R, RAMSEY-GOLDMAN R et al.: History of infection before the onset of juvenile dermatomyositis: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Research Registry. Arthritis Rheum 2005; 53:166-72.
28. MCCANN LJ, JUGGINS AD, MAILLARD SM et al.: The Juvenile Dermatomyositis National Registry and Repository (UK and Ireland) -clinical characteristics of children recruited within the first 5 yr. Rheumatology 2006; 45: 1255-60.
29. PACHMAN LM, HAYFORD JR, CHUNG A et al.: Juvenile dermatomyositis at diagnosis: clinical characteristics of 79 children. J Rheumatol 1998; 25: 1198-204.
30. PACHMAN LM: Juvenile dermatomyositis. Pathophysiology and disease expression. Pediatr Clin North Am 1995; 42: 1071-98.
31. BROWN VE, PILKINGTON CA, FELDMAN BM, DAVIDSON J: An international consensus survey of the diagnostic criteria for juvenile dermatomyositis (JDM). Rheumatology 2006; 45: 990-3.
32. STRINGER E, OTA S, BOHNSACK J et al.: Diversity of treatment approaches to juvenile dermatomyositis across North America: the Childhood Arthritis and Rheumatology Research Alliance (CARRA) JDM treatment survey. Arthritis Rheum 2008; 58: S255.
33. STRINGER E, FELDMAN BM: Advances in the treatment of juvenile dermatomyositis. Curr Opin Rheumatol 2006; 18: 503-6.
34. KIM S, EL-HALLAK M, DEDEOGLU F, ZURAKOWSKI D, FUHLBRIGGE RC, SUNDEL RP: Complete and sustained remission of juvenile dermatomyositis resulting from aggressive treatment. Arthritis Rheum 2009; 60: 1825-30.
35. OLSON NY, LINDSLEY CB: Adjunctive use of hydroxychloroquine in childhood dermatomyositis. J Rheumatol 1989; 16: 1545-7.
36. RILEY P, MAILLARD SM, WEDDERBURN LR, WOO P, MURRAY KJ, PILKINGTON CA: Intravenous cyclophosphamide pulse therapy in juvenile dermatomyositis. A review of efficacy and safety. Rheumatology 2004; 43: 491-6.
37. LEHMAN TJ, SHERRY DD, WAGNER-WEINER L et al.: Intermittent intravenous cyclophosphamide therapy for lupus nephritis. J Pediatr 1989; 114: 1055-60.
38. RILEY P, MCCANN LJ, MAILLARD SM, WOO P, MURRAY KJ, PILKINGTON CA: Effectiveness of infliximab in the treatment of refractory juvenile dermatomyositis with calcinosis. Rheumatology 2008; 47: 877-80.
39. COOPER MA, WILLINGHAM DL, BROWN DE, FRENCH AR, SHIH FF, WHITE AJ: Rituximab for the treatment of juvenile dermatomyositis: a report of four pediatric patients. Arthritis Rheum 2007; 56: 3107-11.
40. AMBLER GR, CHAITOW J, ROGERS M, MCDONALD DW, OUVRIER RA: Rapid improvement of calcinosis in juvenile dermatomyositis with alendronate therapy. J Rheumatol 2005; 32:1837-9.